Juvenescence Puts the Focus on National Keto Day with Metabolic Switch January 05, 2022 January 5 is National Keto Day. Started two years ago by The Vitamin Shoppe, the day serves to bring awareness to the ketogenic diet and its health benefits.
LyGenesis Adds Inborn Errors of Metabolism, Orphan Pediatric Indications ... to its Drug Development Pipeline November 16, 2021 LyGenesis announced that it has achieved positive in vitro results of a novel combination drug-biologic product for patients with inborn errors of metabolism, adding these orphan pediatric indications to its...
Juvenescence Debuts New Product to Aid in Supporting a Healthy Metabolism April 15, 2021 Juvenescence Ltd., a longevity biotech and life sciences company announced the launch of Metabolic Switch®, an evidence-based, breakthrough C6 Ketone Di-ester drink that puts the consumer in ketosis to promote...
Juvenescence Appoints Dr. Grazia Piizzi as Chief Scientific Officer April 06, 2021 Juvenescence announces that Dr. Grazia Piizzi has joined its Executive Management Team as Chief Scientific Officer.
Juvenescence Partner AgeX Therapeutics Announces Preprint Article Relating to Regeneration, Aging, and Cancer March 12, 2021 AgeX Therapeutics announced the online publication of data relating to regeneration, aging, and cancer in bioRxiv.
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement March 02, 2021 AgeX Therapeutics and LyGenesis announced today that they will proceed to negotiate an agreement for a merger of the two companies.
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease December 30, 2020 LyGenesis, Inc. announced that the FDA has cleared its Investigational New Drug application and a study will be conducted on the safety and efficacy of its first-in-class novel cell therapy...
Juvenescence Partner AgeX Therapeutics Sublicenses Stem Cell Line for Development of Covid-19 Therapy October 28, 2020 AgeX Therapeutics announced that ImStem has obtained a non-exclusive, royalty-bearing sublicense from AgeX for development of ImStem’s investigational product candidate IMS001 for development in COVID-19 and ARDS from other causes....
Juvenescence Announces Licensing Agreement with Evgen Pharma PLC September 15, 2020 Juvenescence announces a partnership with Evgen Pharma PLC to license its sulforaphane Sulforadex® stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.
Relation Therapeutics Receives $1.3M Grant From the Gates Foundation to Identify Covid-19 Therapeutic Candidates September 01, 2020 Relation Therapeutics, announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.
LyGenesis Announces a New Peer-Reviewed Publication Expanding its Liver Regeneration Technology August 27, 2020 LyGenesis, a clinical-stage biotechnology company announced today the publication of a new peer-reviewed paper published in journal Hepatology on its organ regeneration technology.
G3 Therapeutics and Juvenescence form Juvenomics June 01, 2020 Juvenescence Limited and G3 Therapeutics announced the formation of Juvenomics Limited, a joint venture between the two parent companies.
